Fortress Biotech, Inc. (FBIO)

The stock plunged after the FDA issued a Complete Response Letter for CUTX-101 in October 2025 due to manufacturing facility deficiencies. In February 2026, Cyprium Therapeutics announced an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $205 million, and Avenue Therapeutics entered into an exclusive worldwide license agreement for ATX-04. Journey Medical Corporation reported its full-year 2025 financial results in March 2026. The stock price moved down in late March 2026, with trading volume exceeding the daily average. Fortress Biotech reported its 2025 financial results in March 2026, highlighting the FDA approval of ZYCUBO® and the sale of the PRV, but the stock declined. In April 2026, the stock price rose above its 200-day moving average. As of April 7, 2026, the share price was $2.35, representing a 64.34% increase from April 8, 2025.

Information regarding specific demand seasonality for Fortress Biotech, Inc.'s products and services is not available. While significant seasonality may not be a primary factor for all its products, some dermatology products could potentially experience seasonal fluctuations in demand.

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products, operating primarily in Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The company's portfolio includes marketed prescription pharmaceutical products and programs in development across various medical therapy areas. Its marketed dermatology products are commercialized by its subsidiary Journey Medical Corporation. The company's pipeline features late-stage product candidates such as intravenous Tramadol, CUTX-101 (ZYCUBO®), UNLOXCYT, Olafertinib, CAEL-101, and Triplex, as well as early-stage and preclinical candidates including Dotinurad and various glioblastoma treatments.

Fortress Biotech, Inc. is headquartered in Bay Harbor Islands, Florida, with another location in Waltham, Massachusetts. Its common stock is traded on Nasdaq, and some of its products are available in several countries, including Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States.

Fortress Biotech's brand reputation has been influenced by regulatory and business events. The FDA's Complete Response Letter for CUTX-101 had a negative impact, while the subsequent FDA approval of ZYCUBO® and the sale of the Rare Pediatric Disease Priority Review Voucher positively impacted its standing. MarketBeat indicates a moderate to above-average reputation within its industry. A historical note on Wikipedia mentions that the article may have been created or edited in return for undisclosed payments, which could be a minor reputational concern.

Fortress Biotech's ownership is a mix of institutional, insider, and public/individual investors. Institutional investors hold approximately 9.17% to 16.80% of the stock, insiders hold 28.36%, and public companies and individual investors hold 54.85%. Major institutional owners include Vanguard Group Inc, Opaleye Management Inc., Summit Financial, LLC, Shikiar Asset Management Inc, Geode Capital Management, Llc, Northern Trust Corp, Susquehanna International Group, Llp, Sculptor Capital LP, and BlackRock, Inc. David Jin owns the most shares of Fortress Biotech.